Evidence map›Paper›PMID 42279264›Full record

ArticleCancers2026

Molecular Characterization of

Fernando Daniel García-Ayala, María de la Luz Ayala-Madrigal, Jorge Peregrina-Sandoval, José Miguel Moreno-Ortiz, Anahí González-Mercado, Ramón Antonio Franco-Topete, Jesús Alonso Valenzuela-Pérez, Nelly Margarita Macías-Gómez, Beatriz Armida Flores-López, Melva Gutiérrez-Angulo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fernando Daniel García-AyalaInstituto de Genética Humana "Dr. Enrique Corona Rivera", Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0009-0004-9215-7191
María de la Luz Ayala-MadrigalInstituto de Genética Humana "Dr. Enrique Corona Rivera", Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-8875-5624
Jorge Peregrina-SandovalPrograma de Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
José Miguel Moreno-OrtizInstituto de Genética Humana "Dr. Enrique Corona Rivera", Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-7555-9851
Anahí González-MercadoInstituto de Genética Humana "Dr. Enrique Corona Rivera", Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-8005-1304
Ramón Antonio Franco-TopeteDepartamento de Microbiología y Patología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-9080-6192
Jesús Alonso Valenzuela-PérezServicio de Colon y Recto, Hospital Civil "Dr. Juan I. Menchaca", Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0003-3549-8219
Nelly Margarita Macías-GómezLaboratorio de Genética Humana, Centro Universitario del Sur, Universidad de Guadalajara, Ciudad Guzmán 49000, Jalisco, Mexico.ORCID 0000-0002-0878-2401
Beatriz Armida Flores-LópezDepartamento de Ciclo de Vida, Facultad de Medicina, Universidad Autónoma de Guadalajara, Zapopan 45129, Jalisco, Mexico.ORCID 0000-0003-1965-7654
Melva Gutiérrez-AnguloInstituto de Genética Humana "Dr. Enrique Corona Rivera", Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0003-3848-8892

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesColorectal cancer (CRC) represents a major public health problem in Mexico and is among the malignancies with the highest morbidity and mortality. Alterations in

methodsTumor samples from 142 patients who underwent surgical resection without neoadjuvant treatment were analyzed. DNA was extracted from tumor tissue.

resultsForty-three heterozygous variants were identified in 106/142 patients, representing 75% of the cohort. Thirty-one patients carried oncogenic variants, mainly clustered within the DNA-binding domain and involving hotspot residues such as Arg175, Tyr220, Gly245, Arg248, Arg273, and Arg282. Nuclear p53 expression was observed in 9/40 tumors, whereas all adjacent tissues were negative.

conclusions

Indexed as

colorectal cancerDNA-binding domainimmunohistochemistryMexican patientsp53somatic variantsTP53 gene

Identifiers

PMID42279264
PMCPMC13255983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.